Portola Pharma (PTLA) Tops Q3 EPS by 19c

Portola Pharma (NASDAQ: PTLA) reported Q3 EPS of ($1.05), $0.19 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $2.45 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance